STOCK TITAN

TScan Therapeutics (TCRX) Stock News, Dec 2024-Aug 2025

TCRX NASDAQ

TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.

Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) reported Q2 2025 financial results and provided updates on its TCR-T therapy programs. The company reported revenue of $3.1 million and a net loss of $37.0 million. Key developments include plans to dose first solid tumor patients with multiplex TCR-T in Q3 2025 and present two-year relapse data from the ALLOHA™ Phase 1 heme trial by year-end.

The company's cash position stands at $218.0 million, expected to fund operations into Q1 2027. TScan plans to initiate a registrational trial for TSC-101 in H2 2025 and file an IND for TSC-102-A0301. Initial safety and response data from the PLEXI-T trial is expected in Q1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
-
Rhea-AI Summary

TScan Therapeutics (NASDAQ: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 4:55 p.m. Eastern Time at the Marriott Marquis in New York. Investors and interested parties can access the presentation webcast through the "Events and Presentations" section on TScan's website at ir.tscan.com, with the replay remaining available for 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.40%
Tags
conferences
-
Rhea-AI Summary
TScan Therapeutics (TCRX) reported Q1 2025 financial results and provided corporate updates. The company reported a net loss of $34.1 million on revenue of $2.2 million. R&D expenses increased to $29.8 million, while G&A expenses rose to $8.6 million. TScan maintains a strong financial position with $251.7 million in cash and equivalents, expected to fund operations into Q1 2027. Key upcoming milestones include updates from PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 trials by year-end, plans to initiate a TSC-101 registrational trial in H2 2025, and filing an IND for TSC-102-A0301. The company appointed Stephen Camiolo as SVP of Market Access and remains on track to dose its first multiplex TCR-T therapy patient in H1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.33%
Tags
Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its upcoming presentation at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.

The event will take place from May 13-17 in New Orleans, LA, with both in-person and virtual attendance options. The company will present a poster focused on "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."

  • Presentation Date: Tuesday, May 13
  • Time: 6:00 - 7:30 p.m. Central Time
  • Location: Poster Hall, Hall I2
  • Abstract Number: AMA1180

The presentation materials will be made available on TScan's website (tscan.com) in the "Publications" section after the presentation concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for April 7, 2025, at 9:30 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com. The replay will remain available for 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
conferences
-
Rhea-AI Summary

TScan Therapeutics (TCRX) has appointed Stephen Camiolo as Senior Vice President of Market Access, bringing over 25 years of industry experience. Camiolo, who most recently served as Vice President of National Cell Therapy Account Teams at Iovance Biotherapeutics, has led 16 successful product launches, including three cell therapies.

The appointment comes as TScan prepares to launch a pivotal trial of TSC-101 for treating residual disease and preventing relapse in patients with AML, ALL, and MDS later this year. The company continues to advance enrollment in its PLEXI-T™ solid tumor program.

Prior to joining TScan, Camiolo held leadership positions at Iovance, where he led the strategic launch of AMTAGVI®, CRISPR Therapeutics, Gilead Sciences, and Kite Pharma, focusing on market access, pricing strategy, and commercial operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
management
Rhea-AI Summary

TScan Therapeutics (NASDAQ: TCRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its cancer treatment pipeline. The company's ALLOHA™ Phase 1 heme trial showed promising results with only 2 of 26 patients relapsing compared to 4 of 12 in the control arm.

Key financial highlights include: Q4 2024 revenue of $0.7M (down from $7.2M in Q4 2023), full-year revenue of $2.8M (down from $21M in 2023), and a Q4 net loss of $35.8M. The company secured $30M through a registered direct offering at a 37% premium and refinanced its debt with a $52.5M term loan from SVB.

R&D expenses increased to $107.4M for 2024 (from $88.2M in 2023) due to expanded clinical trials. With $290.1M in cash and equivalents, TScan expects to fund operations into Q1 2027. The company plans to initiate a registration trial for TSC-101 in H2 2025 and anticipates presenting multiplex TCR-T therapy data in the second half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
-
Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.

Investors and interested parties can access the presentation through a webcast available on the 'Events and Presentations' section of TScan's website at ir.tscan.com. The webcast recording will remain accessible on the company's website for 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
conferences
-
Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company specializing in TCR-engineered T cell therapies for cancer treatment, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company will engage in a fireside chat scheduled for Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com. The presentation recording will remain available for replay on the company's website for 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
conferences
Rhea-AI Summary

TScan Therapeutics (NASDAQ: TCRX) has secured a $30 million registered direct offering through the sale of pre-funded warrants to Lynx1 Capital Management LP and its advised fund. The warrants, priced at $4.00 each, will allow the purchase of up to 7,500,000 shares of voting common stock at $0.0001 per share, representing a 37% premium to the last closing price and a 34% premium over the 10-day volume weighted average closing price.

The financing, expected to close around December 27, 2024, extends TScan's operational runway from Q4 2026 to Q1 2027. The transaction builds upon Lynx1's existing investment in TScan, demonstrating continued support for the company's development of TCR-T cell therapies for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags

FAQ

What is the current stock price of TScan Therapeutics (TCRX)?

TScan Therapeutics (TCRX) last closed at $0.1606.

What is the market cap of TScan Therapeutics (TCRX)?

The market cap of TScan Therapeutics (TCRX) is approximately $10.9M.